Precision Medical World Conference 2022

June 28-30 – Santa Clara Convention Center, CA

Agendia is excited to attend PMWC 2022 Silicon Valley

We will be showcasing the most recent data which builds upon existing clinical research that demonstrates the efficacy of MammaPrint and BluePrint testing to support treatment planning decisions, highlights Agendia’s ongoing trials that have the potential to impact patient treatment and outcomes.

PMWC Showcase Presentation details:

Title: Expanding the Clinical Utility of Genomic Profiling in Early-Stage Breast Cancer
Speaker: William Audeh, MD
Venue: Track 7, Great America Meeting Room K
Date: Tuesday, June 28
Time: 2:30 PM – 2:45 PM PST
Presentation Summary: This presentation will empower you with data demonstrating the utility of Agendia’s assays, MammaPrint and BluePrint, for patients with breast cancer. Review the latest data and learn about the real-world impact of MammaPrint and BluePrint. Please join us for an informative, interactive session.

Visit Agendia’s at Booth #D2520

Visit our booth for more information and to speak with a member of our team.


About the speaker

William Audeh, MD, MS

William Audeh, Agendia’s Chief Medical Officer, is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles. Prior to joining Agendia, and in addition to his clinical practice, he served as the former Director of the Cedars-Sinai Cancer Center and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh has been Principal Investigator on a wide variety of national and international clinical and translational trials, and has authored numerous publications in the field of breast cancer, cancer genomics and targeted cancer therapy.

Have Questions? Contact Us Today.

  • This field is for validation purposes and should be left unchanged.


Trusted by leading physicians and institutions around the world

Genomic Testing Cell Photo

Landmark Trials

Data on the validation and utility of MammaPrint and BluePrint for patients with early stage breast cancer.

See the mindact trial
Two women reading about genomic breast cancer results

Latest News

Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients […]

Read the article

Who We Are

Our purpose, our story our vision. Hear how Agendia fits into the evolving landscape of technology and cancer care.

View Our Video